Literature DB >> 18365797

Adding motivational interviewing to exposure and ritual prevention for obsessive-compulsive disorder: an open pilot trial.

Helen Blair Simpson1, Allan Zuckoff, Jessica R Page, Martin E Franklin, Edna B Foa.   

Abstract

Exposure and ritual prevention (EX/RP) is an efficacious treatment for obsessive-compulsive disorder (OCD), but high dropout rates and variable treatment adherence limit its effectiveness. Motivational interviewing (MI) has shown promise as an adjunct to symptom-focused treatments for improving treatment adherence and outcomes. The authors developed a manual integrating MI with EX/RP, consisting of three information-gathering/motivational enhancement sessions and 15 EX/RP sessions with an optional MI module to be used as needed. Six patients with moderate to severe OCD symptoms (Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score> or =16) underwent treatment. Five showed a decrease in their baseline Y-BOCS scores and an increase in their quality of life, with three achieving an excellent response (i.e. Y-BOCS< or =12 at Session 18). The authors briefly describe the motivational strategies used in the six cases and suggest that integrating MI with standard EX/RP is a promising method to increase and sustain patient engagement with EX/RP. Challenges in combining these treatments and maintaining the integrity of each as well as limitations of the study are discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18365797     DOI: 10.1080/16506070701743252

Source DB:  PubMed          Journal:  Cogn Behav Ther        ISSN: 1650-6073


  13 in total

Review 1.  Psychotherapy for obsessive-compulsive disorder.

Authors:  Eric A Storch; Amy Mariaskin; Tanya K Murphy
Journal:  Curr Psychiatry Rep       Date:  2009-08       Impact factor: 5.285

2.  The role of treatment expectancy in youth receiving exposure-based CBT for obsessive compulsive disorder.

Authors:  Adam B Lewin; Tara S Peris; R Lindsey Bergman; James T McCracken; John Piacentini
Journal:  Behav Res Ther       Date:  2011-06-15

3.  Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?

Authors:  Michael G Wheaton; Hanga Galfalvy; Shari A Steinman; Melanie M Wall; Edna B Foa; H Blair Simpson
Journal:  Behav Res Ther       Date:  2016-07-29

Review 4.  Cognitive behavioral therapy for substance use disorders.

Authors:  R Kathryn McHugh; Bridget A Hearon; Michael W Otto
Journal:  Psychiatr Clin North Am       Date:  2010-09

5.  Motivational Interviewing as an Adjunct to Cognitive Behavior Therapy for Anxiety Disorders: A Critical Review of the Literature.

Authors:  Cameron L Randall; Daniel W McNeil
Journal:  Cogn Behav Pract       Date:  2017-08

6.  Patient utilization of cognitive-behavioral therapy for OCD.

Authors:  Maria C Mancebo; Jane L Eisen; Nicholas J Sibrava; Ingrid R Dyck; Steven A Rasmussen
Journal:  Behav Ther       Date:  2011-03-05

7.  Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trial.

Authors:  Henny A Westra; Hal Arkowitz; David J A Dozois
Journal:  J Anxiety Disord       Date:  2009-07-14

8.  Overcoming barriers to disseminating exposure therapies for anxiety disorders: a pilot randomized controlled trial of training methods.

Authors:  Melanie S Harned; Linda A Dimeff; Eric A Woodcock; Julie M Skutch
Journal:  J Anxiety Disord       Date:  2011-03

9.  Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?

Authors:  Jennifer M Park; Brent J Small; Daniel A Geller; Tanya K Murphy; Adam B Lewin; Eric A Storch
Journal:  J Child Fam Stud       Date:  2014-07-01

10.  Predictors of treatment outcome and attrition in adults with hoarding disorder.

Authors:  Catherine R Ayers; James O E Pittman; Eliza J Davidson; Mary E Dozier; Tina L Mayes; Erin Almklov
Journal:  J Obsessive Compuls Relat Disord       Date:  2018-08-09       Impact factor: 1.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.